CEO John C.M. Farquhar Sells 22,562 Shares in Hear
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy HTFL?
Source: Yahoo Finance
- Executive Sell-off: On April 10, 2026, Hear's CEO John C.M. Farquhar sold 22,562 shares, which may raise concerns about the company's future prospects, as executive sell-offs are often perceived as a lack of confidence in the company.
- Market Reaction: Such executive sell-offs can lead to decreased investor confidence in Hear, potentially impacting its stock performance, especially in the current market environment where investors are highly sensitive to corporate governance and executive actions.
- Impact on Shareholding: This share sale could affect Hear's shareholder structure, particularly if the shares sold represent a significant portion, which may trigger follow-on selling from other investors, further exacerbating stock price volatility.
- Future Outlook: While the sell-off may have a negative short-term impact on stock prices, if Hear can release positive earnings reports or strategic plans in the future, it may still restore market confidence and attract renewed investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HTFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.050
Low
35.00
Averages
38.60
High
40.00
Current: 29.050
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CEO John C.M. Farquhar Sells 22,562 Shares in Hear
- Executive Sell-off: On April 10, 2026, Hear's CEO John C.M. Farquhar sold 22,562 shares, which may raise concerns about the company's future prospects, as executive sell-offs are often perceived as a lack of confidence in the company.
- Market Reaction: Such executive sell-offs can lead to decreased investor confidence in Hear, potentially impacting its stock performance, especially in the current market environment where investors are highly sensitive to corporate governance and executive actions.
- Impact on Shareholding: This share sale could affect Hear's shareholder structure, particularly if the shares sold represent a significant portion, which may trigger follow-on selling from other investors, further exacerbating stock price volatility.
- Future Outlook: While the sell-off may have a negative short-term impact on stock prices, if Hear can release positive earnings reports or strategic plans in the future, it may still restore market confidence and attract renewed investor interest.
See More
Heartflow Files Patent Infringement Lawsuit Against Cleerly
- Patent Infringement Lawsuit: Heartflow (HTFL) has filed a patent infringement lawsuit against Cleerly in the U.S. District Court for the Eastern District of Texas, seeking permanent injunction and damages, indicating a strong intent to protect its technology.
- Identified Infringing Products: Heartflow claims that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe six of its patents from 2012 to 2018, suggesting that Cleerly's products entered the market after Heartflow's innovations, potentially impacting Cleerly's competitive position.
- Expected Legal Consequences: This lawsuit could result in significant damages and market access restrictions for Cleerly, affecting its future product development and market strategy, thereby increasing uncertainty for investors.
- Industry Impact Analysis: Heartflow's actions not only safeguard its intellectual property but may also trigger a patent battle within the medical technology sector, prompting other companies to enhance their focus on patent compliance and protection.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
HeartFlow Executive Stock Transaction Overview
- Transaction Overview: HeartFlow's Chief Medical Officer Rogers Campbell exercised 67,017 options and immediately sold 64,533 shares of common stock for approximately $1.66 million, indicating routine liquidity management under a pre-arranged plan.
- Ownership Changes: This transaction reduced Campbell's direct common stock holdings from 288,591 to 78,518 shares, a decrease of about 72.8%, while indirect holdings remained unchanged, suggesting he still maintains significant control over the company.
- Future Potential: Campbell retains direct stock options, providing substantial future conversion potential and signaling ongoing alignment with share price performance, despite the significant reduction in direct holdings.
- Company Growth Outlook: HeartFlow is guiding for 2026 revenue between $218 million and $222 million, reflecting continued growth in its AI-driven cardiac imaging platform, and despite ongoing net losses, investors remain optimistic about its strong revenue growth trajectory.
See More
HeartFlow CMO Executes Options and Sells Shares
- Trading Overview: HeartFlow's CMO, Rogers Campbell, exercised 67,017 options and sold 64,533 shares on March 19, 2026, generating approximately $1.66 million at an average price of $25.69 per share, indicating a strategic liquidity management approach by the executive.
- Shareholding Changes: This transaction reduced Campbell's direct common stock holdings by 22.36%, while he retains 145,540 shares in indirect holdings, suggesting sustained confidence in the company's future; the transaction was executed under a pre-arranged plan, reflecting routine management operations.
- Financial Performance Highlights: HeartFlow reported full-year 2025 revenue of about $176 million, a 40% year-over-year increase, with fourth-quarter revenue reaching $49.1 million and gross margins nearing 80%, showcasing strong market demand for its AI-powered cardiac imaging platform.
- Future Outlook: Management guides for 2026 revenue between $218 million and $222 million, implying continued double-digit growth; despite ongoing net losses, robust revenue growth provides investor confidence, indicating that investments in commercialization and R&D are sustainable.
See More
CEO John C.M. Farquhar Sells 22,562 Shares in Hear
- Executive Sell-off: On April 10, 2026, Hear's CEO John C.M. Farquhar sold 22,562 shares, which may raise concerns about the company's future prospects, as executive sell-offs are often perceived as a lack of confidence in the company.
- Market Reaction: Such executive sell-offs can lead to decreased investor confidence in Hear, potentially impacting its stock performance, especially in the current market environment where investors are highly sensitive to corporate governance and executive actions.
- Impact on Shareholding: This share sale could affect Hear's shareholder structure, particularly if the shares sold represent a significant portion, which may trigger follow-on selling from other investors, further exacerbating stock price volatility.
- Future Outlook: While the sell-off may have a negative short-term impact on stock prices, if Hear can release positive earnings reports or strategic plans in the future, it may still restore market confidence and attract renewed investor interest.
See More
Heartflow Files Patent Infringement Lawsuit Against Cleerly
- Patent Infringement Lawsuit: Heartflow (HTFL) has filed a patent infringement lawsuit against Cleerly in the U.S. District Court for the Eastern District of Texas, seeking permanent injunction and damages, indicating a strong intent to protect its technology.
- Identified Infringing Products: Heartflow claims that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe six of its patents from 2012 to 2018, suggesting that Cleerly's products entered the market after Heartflow's innovations, potentially impacting Cleerly's competitive position.
- Expected Legal Consequences: This lawsuit could result in significant damages and market access restrictions for Cleerly, affecting its future product development and market strategy, thereby increasing uncertainty for investors.
- Industry Impact Analysis: Heartflow's actions not only safeguard its intellectual property but may also trigger a patent battle within the medical technology sector, prompting other companies to enhance their focus on patent compliance and protection.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
HeartFlow Executive Stock Transaction Overview
- Transaction Overview: HeartFlow's Chief Medical Officer Rogers Campbell exercised 67,017 options and immediately sold 64,533 shares of common stock for approximately $1.66 million, indicating routine liquidity management under a pre-arranged plan.
- Ownership Changes: This transaction reduced Campbell's direct common stock holdings from 288,591 to 78,518 shares, a decrease of about 72.8%, while indirect holdings remained unchanged, suggesting he still maintains significant control over the company.
- Future Potential: Campbell retains direct stock options, providing substantial future conversion potential and signaling ongoing alignment with share price performance, despite the significant reduction in direct holdings.
- Company Growth Outlook: HeartFlow is guiding for 2026 revenue between $218 million and $222 million, reflecting continued growth in its AI-driven cardiac imaging platform, and despite ongoing net losses, investors remain optimistic about its strong revenue growth trajectory.
See More
HeartFlow CMO Executes Options and Sells Shares
- Trading Overview: HeartFlow's CMO, Rogers Campbell, exercised 67,017 options and sold 64,533 shares on March 19, 2026, generating approximately $1.66 million at an average price of $25.69 per share, indicating a strategic liquidity management approach by the executive.
- Shareholding Changes: This transaction reduced Campbell's direct common stock holdings by 22.36%, while he retains 145,540 shares in indirect holdings, suggesting sustained confidence in the company's future; the transaction was executed under a pre-arranged plan, reflecting routine management operations.
- Financial Performance Highlights: HeartFlow reported full-year 2025 revenue of about $176 million, a 40% year-over-year increase, with fourth-quarter revenue reaching $49.1 million and gross margins nearing 80%, showcasing strong market demand for its AI-powered cardiac imaging platform.
- Future Outlook: Management guides for 2026 revenue between $218 million and $222 million, implying continued double-digit growth; despite ongoing net losses, robust revenue growth provides investor confidence, indicating that investments in commercialization and R&D are sustainable.
See More
